Ausgabe 2/2019
Inhalt (23 Artikel)
Cancer immunotherapy: the art of targeting the tumor immune microenvironment
Jesse Lopes da Silva, Alexssandra Lima S. Dos Santos, Natalia Cristina Cardoso Nunes, Flora de Moraes Lino da Silva, Carlos Gil Moreira Ferreira, Andreia Cristina de Melo
The role of apoptosis defects in malignant mesothelioma pathogenesis with an impact on prognosis and treatment
Vasiliki Galani, Anna Varouktsi, Stamatis S. Papadatos, Antigoni Mitselou, Ioannis Sainis, Stavros Constantopoulos, Yotanna Dalavanga
Moxetumomab pasudotox-tdfk for relapsed/refractory hairy cell leukemia: a review of clinical considerations
Carmen F. Nobre, Matthew J. Newman, Anne DeLisa, Pauline Newman
Priming with GM-CSF instead of G-CSF enhances CAG-induced apoptosis of acute monocytic leukemia cells in vitro
Meiqing Lei, Limin Liu, Depei Wu
Ineligibility for the PACIFIC trial in unresectable stage III non-small cell lung cancer patients
Kazutaka Hosoya, Daichi Fujimoto, Hayato Kawachi, Yuki Sato, Mariko Kogo, Kazuma Nagata, Atsushi Nakagawa, Ryo Tachikawa, Shinya Hiraoka, Masaki Kokubo, Keisuke Tomii
Neoadjuvant chemotherapy in patients with advanced endometrial cancer
Olivia R. Khouri, Melissa K. Frey, Fernanda Musa, Franco Muggia, Jessica Lee, Leslie Boyd, John P. Curtin, Bhavana Pothuri
SN-38, the active metabolite of irinotecan, inhibits the acute inflammatory response by targeting toll-like receptor 4
Deysi Viviana Tenazoa Wong, Helder Veras Ribeiro-Filho, Carlos Wagner Souza Wanderley, Caio Abner Vitorino Gonçalves Leite, Jonilson Berlink Lima, Alexia Nathália Brígido Assef, Aurilene Gomes Cajado, Gabriela Loiola Ponte Batista, Rafael Holanda González, Karla Oliveira Silva, Luis Philipi Carvalho Borges, Nylane Maria Nunes Alencar, Diego Veras Wilke, Thiago Mattar Cunha, Ana Carolina Migliorini Figueira, Fernando Queiroz Cunha, Roberto César Pereira Lima-Júnior
Postoperative chemotherapy as adjuvant treatment for endometrioid adenocarcinoma: early stage vs late stage
Mengmeng Lu, Jiaojiao Zheng, Nana Xu, Han Lin, Shaogui Wan
Second-line FOLFIRI plus ramucirumab with or without prior bevacizumab for patients with metastatic colorectal cancer
Takeshi Suzuki, Eiji Shinozaki, Hiroki Osumi, Izuma Nakayama, Yumiko Ota, Takashi Ichimura, Mariko Ogura, Takeru Wakatsuki, Akira Ooki, Daisuke Takahari, Mitsukuni Suenaga, Keisho Chin, Kensei Yamaguchi
A panel of serum exosomal microRNAs as predictive markers for chemoresistance in advanced colorectal cancer
Guoying Jin, Yuhang Liu, Jia Zhang, Zehua Bian, Surui Yao, Bojian Fei, Leyuan Zhou, Yuan Yin, Zhaohui Huang
Safety, tolerability, and pharmacokinetics of anti-EGFRvIII antibody–drug conjugate AMG 595 in patients with recurrent malignant glioma expressing EGFRvIII
Mark Rosenthal, Richard Curry, David A. Reardon, Erik Rasmussen, Vijay V. Upreti, Michael A. Damore, Haby A. Henary, John S. Hill, Timothy Cloughesy
Phase I study of BGT226, a pan-PI3K and mTOR inhibitor, in Japanese patients with advanced solid cancers
Hironobu Minami, Yutaka Fujiwara, Kei Muro, Masahiko Sato, Atsuko Moriya
Oxaliplatin induces prostaglandin E2 release in vascular endothelial cells
Satoru Matsunuma, Satoko Handa, Daisuke Kamei, Hitomi Yamamoto, Kiyoshi Okuyama, Yasuhisa Kato
A single-arm phase II trial of weekly nanoparticle albumin-bound paclitaxel (nab-paclitaxel) monotherapy after standard of chemotherapy for previously treated advanced non-small cell lung cancer
Yasuhiro Kato, Yusuke Okuma, Kageaki Watanabe, Makiko Yomota, Shoko Kawai, Yukio Hosomi, Tatsuru Okamura
Exposure time versus cytotoxicity for anticancer agents
David M. Evans, Jianwen Fang, Thomas Silvers, Rene Delosh, Julie Laudeman, Chad Ogle, Russell Reinhart, Michael Selby, Lori Bowles, John Connelly, Erik Harris, Julia Krushkal, Larry Rubinstein, James H. Doroshow, Beverly A. Teicher
Effect of ethnicity on vinorelbine pharmacokinetics: a population pharmacokinetics analysis
Aurélie Pétain, Dafang Zhong, Xiaoyan Chen, Zhang Li, Shao Zhimin, Jiang Zefei, Grégoire Zorza, Pierre Ferré
The effects of lapatinib on cardiac repolarization: results from a placebo controlled, single sequence, crossover study in patients with advanced solid tumors
Shodeinde A. Coker, Herbert I. Hurwitz, Sunil Sharma, Ding Wang, Pierre Jordaan, Juan Pablo Zarate, Lionel D. Lewis
Phase I study of ipatasertib as a single agent and in combination with abiraterone plus prednisolone in Japanese patients with advanced solid tumors
Toshihiko Doi, Yutaka Fujiwara, Nobuaki Matsubara, Junichi Tomomatsu, Satoru Iwasa, Akari Tanaka, Chihiro Endo-Tsukude, Shintaro Nakagawa, Shunji Takahashi
Predictive factors for the development of diabetes in cancer patients treated with phosphatidylinositol 3-kinase inhibitors
Gyuri Kim, Myungeun Yoo, Min Hee Hong, Byung-Wan Lee, Eun Seok Kang, Bong-Soo Cha, Hye Ryun Kim, Yong-ho Lee, Byoung Chul Cho
MSI2-TGF-β/TGF-β R1/SMAD3 positive feedback regulation in glioblastoma
Xingjun Jiang, Jun Tan, Yin Wen, Weidong Liu, Shuyu Wu, Lei Wang, Siyi Wangou, Dingyang Liu, Can Du, Bin Zhu, Dan Xie, Caiping Ren
MicroRNA-552 deficiency mediates 5-fluorouracil resistance by targeting SMAD2 signaling in DNA-mismatch-repair-deficient colorectal cancer
Ping Zhao, Yu-guang Ma, Yang Zhao, Di Liu, Zhi-jun Dai, Chang-you Yan, Hai-tao Guan
An open label phase 1 study evaluation safety, tolerability, and maximum tolerated dose of oral administration of irinotecan in combination with capecitabine
I. Kümler, R. L. Eefsen, Peter Grundtvig Sørensen, S. Theile, A. Fullerton, P. G. Nielsen, Benny Vittrup Jensen, D. L. Nielsen
CNS penetration of the CDK4/6 inhibitor ribociclib in non-tumor bearing mice and mice bearing pediatric brain tumors
Yogesh T. Patel, Abigail Davis, Suzanne J. Baker, Olivia Campagne, Clinton F. Stewart